Morgans, A. K., Niazi, T., Shore, N. D., Gschwend, J. E., Ross, A., Hope, T. A., Chehrazi-Raffle, A., Supiot, S., Barthélémy, P., Røder, A., Gomes, A. J., Imbroda, B. H., Gratton, M., Ruiz, C. B. C., Joensuu, H., Berre, M. L., Dimova-Dobreva, M., Kuss, I., Fizazi, K. (2025). Darolutamide plus androgen deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps5131